Legal & General Group Plc Has $12.80 Million Holdings in Roivant Sciences Ltd. $ROIV

Legal & General Group Plc lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 589,673 shares of the company’s stock after acquiring an additional 40,344 shares during the period. Legal & General Group Plc’s holdings in Roivant Sciences were worth $12,796,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund raised its stake in shares of Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after purchasing an additional 500 shares during the period. Bessemer Group Inc. boosted its position in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Allworth Financial LP grew its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares in the last quarter. Fifth Third Bancorp raised its position in Roivant Sciences by 15.8% in the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after buying an additional 588 shares during the last quarter. Finally, Utah Retirement Systems raised its position in Roivant Sciences by 3.0% in the 3rd quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock valued at $312,000 after buying an additional 600 shares during the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Melissa B. Epperly sold 41,861 shares of Roivant Sciences stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $28.68, for a total value of $1,200,573.48. Following the completion of the transaction, the director owned 15,804 shares of the company’s stock, valued at $453,258.72. This trade represents a 72.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew Gline sold 289,774 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the transaction, the chief executive officer owned 16,736,116 shares in the company, valued at $488,025,142.56. This represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 945,173 shares of company stock valued at $27,654,456 in the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Down 2.9%

ROIV stock opened at $28.25 on Wednesday. The company has a market cap of $20.32 billion, a price-to-earnings ratio of -47.08 and a beta of 1.13. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $32.79. The business has a 50 day moving average price of $28.65 and a two-hundred day moving average price of $25.48.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The company had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter in the prior year, the business posted ($0.29) EPS. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -1.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ROIV. Sanford C. Bernstein started coverage on Roivant Sciences in a research report on Friday, March 20th. They set an “outperform” rating and a $35.00 price target for the company. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. TD Cowen increased their target price on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Guggenheim lifted their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $33.59.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.